Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27742 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Paul H Sugarbaker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Pseudomyxoma Peritonei, Gastrectomy, Colectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Foundation for Applied Research in Gastrointestinal Oncology.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The absolute requirement for a long‐term favorable result with cytoreductive surgery for pseudomyxoma peritonei is a complete resection of all visible disease. A combination of parietal peritonectomy procedures and visceral resections is required for this to occur. The cytoreductive surgery is supplemented by hyperthermic intraperitoneal chemotherapy.
Methods
We searched our database and secured files for patients who required a total gastrectomy and a total colectomy to achieve a complete cytoreductive surgery. Survival of low‐grade mucinous neoplasm (LAMN) and mucinous appendiceal adenocarcinoma (MACA) histologies were determined. Clinical and histologic variables were assessed for their impact on survival.
Results
Thirteen of 450 patients (2.9%) with LAMN histology and 14 of 186 patients (7.5%) with MACA histology had these visceral resections. Median survival of these 27 patients was 10 years. LAMN and MACA patients showed the same survival. For LAMN histology, this requirement for extensive visceral resection markedly reduced survival ( p < 0.0001). For MACA, there was no adverse impact on survival ( p = 0.4359). Class 4 adverse events caused reduced survival ( p = 0.0014).
Conclusions
A 10‐year median survival accompanies total gastrectomy plus total colectomy for advanced pseudomyxoma peritonei. Systemic chemotherapy and class 4 adverse events reduced survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia, USA.
- Westat, Rockville, Maryland, USA.
Förderung
- Foundation for Applied Research in Gastrointestinal Oncology
Zitieren
APA
Sugarbaker, P. H., & Chang, D. (2024). Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27742
Vancouver
Sugarbaker PH, Chang D. Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27742
BibTeX
@article{Sugarbaker2024,
author = {Sugarbaker, Paul H and Chang, David},
title = {Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27742}
}
EUVIMED